Probes and nano-delivery systems targeting NAD(P)H:quinone oxidoreductase 1: a mini-review

Xuewen Mu, Yun Xu, Zheng Wang, Dunyun Shi

PDF(8156 KB)
PDF(8156 KB)
Front. Chem. Sci. Eng. ›› 2023, Vol. 17 ›› Issue (2) : 123-138. DOI: 10.1007/s11705-022-2194-7
REVIEW ARTICLE

Probes and nano-delivery systems targeting NAD(P)H:quinone oxidoreductase 1: a mini-review

Author information +
History +

Abstract

The two-electron cytoplasmic reductase NAD(P)H:quinone oxidoreductase 1 is expressed in many tissues. NAD(P)H:quinone oxidoreductase 1 is well-known for being highly expressed in most cancers. Therefore, it could be a target for cancer therapy. Because it is a quinone reductase, many bioimaging probes based on quinone structures target NAD(P)H:quinone oxidoreductase 1 to diagnose tumours. Its expression is higher in tumours than in normal tissues, and using target drugs such as β-lapachone to reduce side effects in normal tissues can help. However, the physicochemical properties of β-lapachone limit its application. The problem can be solved by using nanosystems to deliver β-lapachone. This mini-review summarizes quinone-based fluorescent, near-infrared and two-photon fluorescent probes, as well as nanosystems for delivering the NAD(P)H:quinone oxidoreductase 1-activating drug β-lapachone. This review provides valuable information for the future development of probes and nano-delivery systems that target NAD(P)H:quinone oxidoreductase 1.

Graphical abstract

Keywords

NAD(P)H:quinone oxidoreductase 1 / cancer therapy / target / probe / nanosystem

Cite this article

Download citation ▾
Xuewen Mu, Yun Xu, Zheng Wang, Dunyun Shi. Probes and nano-delivery systems targeting NAD(P)H:quinone oxidoreductase 1: a mini-review. Front. Chem. Sci. Eng., 2023, 17(2): 123‒138 https://doi.org/10.1007/s11705-022-2194-7

References

[1]
TedeschiG, ChenS, MasseyV. DT-diaphorase. Redox potential, steady-state, and rapid reaction studies. Journal of Biological Chemistry, 1995, 270( 3): 11981204
[2]
RossD, SiegelD. Functions of NQO1 in cellular protection and CoQ10 metabolism and its potential role as a redox sensitive molecular switch. Frontiers in Physiology, 2017, 8 : 595
CrossRef Google scholar
[3]
HosodaS, NakamuraW, HayashiK. Properties and reaction mechanism of DT diaphorase from rat liver. Journal of Biological Chemistry, 1974, 249( 20): 6416– 6423
CrossRef Google scholar
[4]
LiR, BianchetM A, TalalayP, AmzelL M. The three-dimensional structure of NAD(P)H:quinone reductase, a flavoprotein involved in cancer chemoprotection and chemotherapy: mechanism of the two-electron reduction. Proceedings of the National Academy of Sciences of the United States of America, 1995, 92( 19): 8846– 8850
CrossRef Google scholar
[5]
RossD, KepaJ K, WinskiS L, BeallH D, AnwarA, SiegelD. NAD(P)H:quinone oxidoreductase 1 (NQO1): chemoprotection, bioactivation, gene regulation and genetic polymorphisms. Chemico-Biological Interactions, 2000, 129( 1–2): 77– 97
CrossRef Google scholar
[6]
SiegelD, GustafsonD L, DehnD L, HanJ Y, BoonchoongP, BerlinerL J, RossD. NAD(P)H:quinone oxidoreductase 1: role as a superoxide scavenger. Molecular Pharmacology, 2004, 65( 5): 1238– 1247
CrossRef Google scholar
[7]
BeyerR E, Segura-AguilarJ, Di BernardoS, CavazzoniM, FatoR, FiorentiniD, GalliM C, SettiM, LandiL, LenazG. The role of DT-diaphorase in the maintenance of the reduced antioxidant form of coenzyme Q in membrane systems. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93( 6): 2528– 2532
CrossRef Google scholar
[8]
LieblerD C. The role of metabolism in the antioxidant function of vitamin E. Critical Reviews in Toxicology, 1993, 23( 2): 147– 169
CrossRef Google scholar
[9]
BindoliA, ValenteM, CavalliniL. Inhibition of lipid peroxidation by alpha-tocopherolquinone and α-tocopherol-hydroquinone. Biochemistry International, 1985, 10( 5): 753– 761
[10]
KoharI BacaM SuarnaC StockerR Southwell-KeelyP T. Is α-tocopherol a reservoir for α-tocopheryl hydroquinone? Free Radical Biology & Medicine, 1995, 19( 2): 197– 207
[11]
SiegelD, BoltonE M, BurrJ A, LieblerD C, RossD. The reduction of alpha-tocopherolquinone by human NAD(P)H:quinone oxidoreductase: the role of alpha-tocopherol hydroquinone as a cellular antioxidant. Molecular Pharmacology, 1997, 52( 2): 300– 305
CrossRef Google scholar
[12]
RossD. Quinone reductases multitasking in the metabolic world. Drug Metabolism Reviews, 2004, 36( 3–4): 639– 654
CrossRef Google scholar
[13]
ZhuH, LiY. NAD(P)H:quinone oxidoreductase 1 and its potential protective role in cardiovascular diseases and related conditions. Cardiovascular Toxicology, 2012, 12( 1): 39– 45
CrossRef Google scholar
[14]
ZhuH, JiaZ, MahaneyJ E, RossD, MisraH P, TrushM A, LiY. The highly expressed and inducible endogenous NAD(P)H:quinone oxidoreductase 1 in cardiovascular cells acts as a potential superoxide scavenger. Cardiovascular Toxicology, 2007, 7( 3): 202– 211
CrossRef Google scholar
[15]
MccordJ M, FridovichI. Superoxide dismutase. An enzymic function for erythrocuprein (hemocuprein). Journal of Biological Chemistry, 1969, 244( 22): 6049– 6055
CrossRef Google scholar
[16]
SiegelD, RossD. Immunodetection of NAD(P)H:quinone oxidoreductase 1 (NQO1) in human tissues. Free Radical Biology & Medicine, 2000, 29( 3–4): 246– 253
CrossRef Google scholar
[17]
OhE T, ParkH J. Implications of NQO1 in cancer therapy. BMB Reports, 2015, 48( 11): 609– 617
CrossRef Google scholar
[18]
ZhangK, ChenD, MaK, WuX, HaoH, JiangS. NAD(P)H:quinone oxidoreductase 1 (NQO1) as a therapeutic and diagnostic target in cancer. Journal of Medicinal Chemistry, 2018, 61( 16): 6983– 7003
CrossRef Google scholar
[19]
LevineA J. P53, the cellular gatekeeper for growth and division. Cell, 1997, 88( 3): 323– 331
CrossRef Google scholar
[20]
AsherG, LotemJ, CohenB, SachsL, ShaulY. Regulation of p53 stability and p53-dependent apoptosis by NADH quinone oxidoreductase 1. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98( 3): 1188– 1193
CrossRef Google scholar
[21]
AsherG, LotemJ, KamaR, SachsL, ShaulY. NQO1 stabilizes p53 through a distinct pathway. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99( 5): 3099– 3104
CrossRef Google scholar
[22]
AsherG, LotemJ, SachsL, KahanaC, ShaulY. MDM-2 and ubiquitin-independent p53 proteasomal degradation regulated by NQO1. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99( 20): 13125– 13130
CrossRef Google scholar
[23]
AsherG, BercovichZ, TsvetkovP, ShaulY, KahanaC. 20s proteasomal degradation of ornithine decarboxylase is regulated by NQO1. Molecular Cell, 2005, 17( 5): 645– 655
CrossRef Google scholar
[24]
CornblattB S, YeL, Dinkova-KostovaA T, ErbM, FaheyJ W, SinghN K, ChenM S, StiererT, Garrett-MayerE, ArganiP, DavidsonN E, TalalayP, KenslerT W, VisvanathanK. Preclinical and clinical evaluation of sulforaphane for chemoprevention in the breast. Carcinogenesis, 2007, 28( 7): 1485– 1490
CrossRef Google scholar
[25]
SurhY J. Cancer chemoprevention with dietary phytochemicals. Nature Reviews Cancer, 2003, 3( 10): 768– 780
CrossRef Google scholar
[26]
SchlagerJ J, PowisG. Cytosolic NAD(P)H:(quinone-acceptor)oxidoreductase in human normal and tumor tissue: effects of cigarette smoking and alcohol. International Journal of Cancer, 1990, 45( 3): 403– 409
CrossRef Google scholar
[27]
MaY, KongJ, YanG, RenX, JinD, JinT, LinL, LinZ. NQO1 overexpression is associated with poor prognosis in squamous cell carcinoma of the uterine cervix. BMC Cancer, 2014, 14( 1): 414
CrossRef Google scholar
[28]
YangY, ZhangY, WuQ, CuiX, LinZ, LiuS, ChenL. Clinical implications of high NQO1 expression in breast cancers. Journal of Experimental & Clinical Cancer Research, 2014, 33( 1): 14
CrossRef Google scholar
[29]
LewisA M, OughM, DuJ, TsaoM S, OberleyL W, CullenJ J. Targeting NAD(P)H:quinone oxidoreductase (NQO1) in pancreatic cancer. Molecular Carcinogenesis, 2017, 56( 7): 1825– 1834
CrossRef Google scholar
[30]
MadajewskiB, BoatmanM A, ChakrabartiG, BoothmanD A, BeyE A. Depleting tumor-NQO1 potentiates anoikis and inhibits growth of NSCLC. Molecular Cancer Research, 2016, 14( 1): 14– 25
CrossRef Google scholar
[31]
OhE T, KimJ W, KimJ M, KimS J, LeeJ S, HongS S, GoodwinJ, RuthenborgR J, JungM G, LeeH J, LeeC H, ParkE S, KimC, ParkH J. NQO1 inhibits proteasome-mediated degradation of HIF-1α. Nature Communications, 2016, 7( 1): 13593
CrossRef Google scholar
[32]
MosesM A, BremH, LangerR. Advancing the field of drug delivery: taking aim at cancer. Cancer Cell, 2003, 4( 5): 337– 341
CrossRef Google scholar
[33]
WagnerH. Image-guided conformal radiation therapy planning and delivery for non-small-cell lung cancer. Cancer Control, 2003, 10( 4): 277– 288
CrossRef Google scholar
[34]
AltmanB J, StineZ E, DangC V. From Krebs to clinic: glutamine metabolism to cancer therapy. Nature Reviews. Cancer, 2016, 16( 11): 749
CrossRef Google scholar
[35]
CallahanM K, PostowM A, WolchokJ D. Targeting T cell co-receptors for cancer therapy. Immunity, 2016, 44( 5): 1069– 1078
CrossRef Google scholar
[36]
AwadallahN S, DehnD, ShahR J, Russell NashS, ChenY K, RossD, BentzJ S, ShroyerK R. NQO1 expression in pancreatic cancer and its potential use as a biomarker. Applied Immunohistochemistry & Molecular Morphology, 2008, 16( 1): 24– 31
CrossRef Google scholar
[37]
RazgulinA, MaN, RaoJ. Strategies for in vivo imaging of enzyme activity: an overview and recent advances. Chemical Society Reviews, 2011, 40( 7): 4186– 4216
CrossRef Google scholar
[38]
SiegelR, NaishadhamD, JemalA. Cancer statistics, 2012. CA: a Cancer Journal for Clinicians, 2012, 62( 1): 10– 29
CrossRef Google scholar
[39]
NguyenQ T, OlsonE S, AguileraT A, JiangT, ScadengM, ElliesL G, TsienR Y. Surgery with molecular fluorescence imaging using activatable cell-penetrating peptides decreases residual cancer and improves survival. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107( 9): 4317– 4322
CrossRef Google scholar
[40]
SilversW C, PrasaiB, BurkD H, BrownM L, MccarleyR L. Profluorogenic reductase substrate for rapid, selective, and sensitive visualization and detection of human cancer cells that overexpress nqo1. Journal of the American Chemical Society, 2013, 135( 1): 309– 314
CrossRef Google scholar
[41]
DukeR M, VealeE B, PfefferF M, KrugerP E, GunnlaugssonT. Colorimetric and fluorescent anion sensors: an overview of recent developments in the use of 1,8-naphthalimide-based chemosensors. Chemical Society Reviews, 2010, 39( 10): 3936– 3953
CrossRef Google scholar
[42]
QianX, XiaoY, XuY, GuoX, QianJ, ZhuW. “Alive” dyes as fluorescent sensors: fluorophore, mechanism, receptor and images in living cells. Chemical Communications (Cambridge), 2010, 46( 35): 6418– 6436
CrossRef Google scholar
[43]
McmahonK M, VolpatoM, ChiH Y, MusiwaroP, PoterlowiczK, PengY, ScallyA J, PattersonL H, PhillipsR M, SuttonC W. Characterization of changes in the proteome in different regions of 3D multicell tumor spheroids. Journal of Proteome Research, 2012, 11( 5): 2863– 2875
CrossRef Google scholar
[44]
CoxM C, ReeseL M, BickfordL R, VerbridgeS S. Toward the broad adoption of 3D tumor models in the cancer drug pipeline. ACS Biomaterials Science & Engineering, 2015, 1( 10): 877– 894
CrossRef Google scholar
[45]
FriedrichJ, SeidelC, EbnerR, Kunz-SchughartL A. Spheroid-based drug screen: considerations and practical approach. Nature Protocols, 2009, 4( 3): 309– 324
CrossRef Google scholar
[46]
VinciM, GowanS, BoxallF, PattersonL, ZimmermannM, CourtW, LomasC, MendiolaM, HardissonD, EcclesS A. Advances in establishment and analysis of three-dimensional tumor spheroid-based functional assays for target validation and drug evaluation. BMC Biology, 2012, 10( 1): 29
CrossRef Google scholar
[47]
VahrmeijerA L, HuttemanM, van der VorstJ R, van de VeldeC J, FrangioniJ V. Image-guided cancer surgery using near-infrared fluorescence. Nature Reviews. Clinical Oncology, 2013, 10( 9): 507– 518
CrossRef Google scholar
[48]
NguyenQ T, TsienR Y. Fluorescence-guided surgery with live molecular navigation—a new cutting edge. Nature Reviews Cancer, 2013, 13( 9): 653– 662
CrossRef Google scholar
[49]
KeereweerS, van DrielP B, SnoeksT J, KerrebijnJ D, Baatenburg De JongR J, VahrmeijerA L, SterenborgH J, LowikC W. Optical image-guided cancer surgery: challenges and limitations. Clinical Cancer Research, 2013, 19( 14): 3745– 3754
CrossRef Google scholar
[50]
Van DamG M, ThemelisG, CraneL M, HarlaarN J, PleijhuisR G, KelderW, SarantopoulosA, De JongJ S, ArtsH J, Van Der ZeeA G, BartJ, LowP S, NtziachristosV. Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-alpha targeting: first in-human results. Nature Medicine, 2011, 17( 10): 1315– 1319
CrossRef Google scholar
[51]
KobayashiH, ChoykeP L. Target-cancer-cell-specific activatable fluorescence imaging probes: rational design and in vivo applications. Accounts of Chemical Research, 2011, 44( 2): 83– 90
CrossRef Google scholar
[52]
De MolinerF, BiazruchkaI, KonsewiczK, BensonS, SinghS, LeeJ S, VendrellM. Near-infrared benzodiazoles as small molecule environmentally-sensitive fluorophores. Frontiers of Chemical Science and Engineering, 2022, 16( 1): 128– 135
CrossRef Google scholar
[53]
ShenZ, PrasaiB, NakamuraY, KobayashiH, JacksonM S, MccarleyR L. A near-infrared, wavelength-shiftable, turn-on fluorescent probe for the detection and imaging of cancer tumor cells. ACS Chemical Biology, 2017, 12( 4): 1121– 1132
CrossRef Google scholar
[54]
GongQ, YangF, HuJ, LiT, WangP, LiX, ZhangX. Rational designed highly sensitive NQO1-activated near-infrared fluorescent probe combined with nqo1 substrates in vivo: an innovative strategy for NQO1-overexpressing cancer theranostics. European Journal of Medicinal Chemistry, 2021, 224 : 113707
CrossRef Google scholar
[55]
MendozaM F, HollabaughN M, HettiarachchiS U, MccarleyR L. Human NAD(P)H:quinone oxidoreductase type I (hNQO1) activation of quinone propionic acid trigger groups. Biochemistry, 2012, 51( 40): 8014– 8026
CrossRef Google scholar
[56]
PunganuruS R, MadalaH R, ArutlaV, ZhangR, SrivenugopalK S. Characterization of a highly specific NQO1-activated near-infrared fluorescent probe and its application for in vivo tumor imaging. Scientific Reports, 2019, 9( 1): 8577
CrossRef Google scholar
[57]
ChengZ, ValençaW O, DiasG G, ScottJ, BarthN D, deMoliner F, SouzaG B P, MellanbyR J, VendrellM, daSilva Júnior E N. Natural product-inspired profluorophores for imaging NQO1 activity in tumour tissues. Bioorganic & Medicinal Chemistry, 2019, 27( 17): 3938– 3946
CrossRef Google scholar
[58]
YuanZ, XuM, WuT, ZhangX, ShenY, ErnestU, GuiL, WangF, HeQ, ChenH. Design and synthesis of NQO1 responsive fluorescence probe and its application in bio-imaging for cancer diagnosis. Talanta, 2019, 198 : 323– 329
CrossRef Google scholar
[59]
ZhangJ, LiuH W, HuX X, LiJ, LiangL H, ZhangX B, TanW. Efficient two-photon fluorescent probe for nitroreductase detection and hypoxia imaging in tumor cells and tissues. Analytical Chemistry, 2015, 87( 23): 11832– 11839
CrossRef Google scholar
[60]
ShinW S, LeeM G, VerwilstP, LeeJ H, ChiS G, KimJ S. Mitochondria-targeted aggregation induced emission theranostics: crucial importance of in situ activation. Chemical Science, 2016, 7( 9): 6050– 6059
[61]
XuQ, HeoC H, KimJ A, LeeH S, HuY, KimD, SwamyK M, KimG, NamS J, KimH M, YoonJ. A selective imidazoline-2-thione-bearing two-photon fluorescent probe for hypochlorous acid in mitochondria. Analytical Chemistry, 2016, 88( 12): 6615– 6620
CrossRef Google scholar
[62]
XuQ, HeoC H, KimG, LeeH W, KimH M, YoonJ. Development of imidazoline-2-thiones based two-photon fluorescence probes for imaging hypochlorite generation in a co-culture system. Angewandte Chemie International Edition, 2015, 54( 16): 4890– 4894
CrossRef Google scholar
[63]
KimH M, ChoB R. Small-molecule two-photon probes for bioimaging applications. Chemical Reviews, 2015, 115( 11): 5014– 5055
CrossRef Google scholar
[64]
LiuH W, XuS, WangP, HuX X, ZhangJ, YuanL, ZhangX B, TanW. An efficient two-photon fluorescent probe for monitoring mitochondrial singlet oxygen in tissues during photodynamic therapy. Chemical Communications (Cambridge), 2016, 52( 83): 12330– 12333
CrossRef Google scholar
[65]
LiuY, MengF, HeL, YuX, LinW. Fluorescence behavior of a unique two-photon fluorescent probe in aggregate and solution states and highly sensitive detection of RNA in water solution and living systems. Chemical Communications (Cambridge), 2016, 52( 57): 8838– 8841
CrossRef Google scholar
[66]
MaoZ, FengW, LiZ, ZengL, LvW, LiuZ. Nir in, far-red out: developing a two-photon fluorescent probe for tracking nitric oxide in deep tissue. Chemical Science, 2016, 7( 8): 5230– 5235
[67]
KwonN, ChoM K, ParkS J, KimD, NamS J, CuiL, KimH M, YoonJ. An efficient two-photon fluorescent probe for human NAD(P)H:quinone oxidoreductase (hNQO1) detection and imaging in tumor cells. Chemical Communications, 2017, 53( 3): 525– 528
CrossRef Google scholar
[68]
ShinW S, HanJ, VerwilstP, KumarR, KimJ H, KimJ S. Cancer targeted enzymatic theranostic prodrug: precise diagnosis and chemotherapy. Bioconjugate Chemistry, 2016, 27( 5): 1419– 1426
CrossRef Google scholar
[69]
KanedaN, NagataH, FurutaT, YokokuraT. Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Research, 1990, 50( 6): 1715– 1720
[70]
BentleM S, BeyE A, DongY, ReinickeK E, BoothmanD A. New tricks for old drugs: the anticarcinogenic potential of DNA repair inhibitors. Journal of Molecular Histology, 2006, 37( 5–7): 203– 218
CrossRef Google scholar
[71]
BoothmanD A, TraskD K, PardeeA B. Inhibition of potentially lethal DNA damage repair in human tumor cells by beta-lapachone, an activator of topoisomerase I. Cancer Research, 1989, 49( 3): 605– 612
[72]
PinkJ J, PlanchonS M, TagliarinoC, VarnesM E, SiegelD, BoothmanD A. NAD(P)H:quinone oxidoreductase activity is the principal determinant of β-lapachone cytotoxicity. Journal of Biological Chemistry, 2000, 275( 8): 5416– 5424
CrossRef Google scholar
[73]
PlanchonS M, PinkJ J, TagliarinoC, BornmannW G, VarnesM E, BoothmanD A. β-Lapachone-induced apoptosis in human prostate cancer cells: involvement of NQO1/xip3. Experimental Cell Research, 2001, 267( 1): 95– 106
CrossRef Google scholar
[74]
OughM, LewisA, BeyE A, GaoJ, RitchieJ M, BornmannW, BoothmanD A, OberleyL W, CullenJ J. Efficacy of β-lapachone in pancreatic cancer treatment: exploiting the novel, therapeutic target NQO1. Cancer Biology & Therapy, 2005, 4( 1): 95– 102
CrossRef Google scholar
[75]
BegM S, HuangX, SilversM A, GerberD E, BolluytJ, SarodeV, FattahF, DeberardinisR J, MerrittM E, XieX J, LeffR, LaheruD, BoothmanD A. Using a novel NQO1 bioactivatable drug, beta-lapachone (ARQ761), to enhance chemotherapeutic effects by metabolic modulation in pancreatic cancer. Journal of Surgical Oncology, 2017, 116( 1): 83– 88
CrossRef Google scholar
[76]
ZadaS, HwangJ S, AhmedM, LaiT H, PhamT M, KimD H, KimD R. Protein kinase a activation by beta-lapachone is associated with apoptotic cell death in NQO1overexpressing breast cancer cells. Oncology Reports, 2019, 42( 4): 1621– 1630
[77]
SongC W, ChaeJ J, ChoiE K, HwangT S, KimC, LimB U, ParkH J. Anti-cancer effect of bio-reductive drug β-lapachon is enhanced by activating NQO1 with heat shock. International Journal of Hyperthermia, 2008, 24( 2): 161– 169
CrossRef Google scholar
[78]
ParkH J ChoiE K ChoiJ AhnK J KimE J JiI M KookY H AhnS D WilliamsB GriffinR BoothmanD A LeeC K SongC W. Heat-induced up-regulation of NAD(P)H:quinone oxidoreductase potentiates anticancer effects of β-lapachone . Clinical Cancer Research, 2005, 11(24 Pt 1): 8866- 8871
[79]
SuzukiM, AmanoM, ChoiJ, ParkH J, WilliamsB W, OnoK, SongC W. Synergistic effects of radiation and β-lapachone in DU-145 human prostate cancer cells in vitro. Radiation Research, 2006, 165( 5): 525– 531
CrossRef Google scholar
[80]
ChoiE K, TeraiK, JiI M, KookY H, ParkK H, OhE T, GriffinR J, LimB U, KimJ S, LeeD S, BoothmanD A, LorenM, SongC W, ParkH J. Upregulation of NAD(P)H:Quinone oxidoreductase by radiation potentiates the effect of bioreductive β-lapachone on cancer cells. Neoplasia, 2007, 9( 8): 634– 642
CrossRef Google scholar
[81]
LiL S, ReddyS, LinZ H, LiuS, ParkH, ChunS G, BornmannW G, ThibodeauxJ, YanJ, ChakrabartiG, XieX J, SumerB D, BoothmanD A, YordyJ S. NQO1-mediated tumor-selective lethality and radiosensitization for head and neck cancer. Molecular Cancer Therapeutics, 2016, 15( 7): 1757– 1767
CrossRef Google scholar
[82]
LambertiM J, VittarN B, Da Silva FdeC, FerreiraV F, RivarolaV A. Synergistic enhancement of antitumor effect of β-lapachone by photodynamic induction of quinone oxidoreductase (NQO1). Phytomedicine, 2013, 20( 11): 1007– 1012
CrossRef Google scholar
[83]
LambertiM J, Morales VasconsueloA B, ChiaramelloM, FerreiraV F, Macedo OliveiraM, Baptista FerreiraS, RivarolaV A, Rumie VittarN B. NQO1 induction mediated by photodynamic therapy synergizes with β-lapachone-halogenated derivative against melanoma. Biomedicine and Pharmacotherapy, 2018, 108 : 1553– 1564
CrossRef Google scholar
[84]
NasongklaN, WiedmannA F, BrueningA, BemanM, RayD, BornmannW G, BoothmanD A, GaoJ. Enhancement of solubility and bioavailability of β-lapachone using cyclodextrin inclusion complexes. Pharmaceutical Research, 2003, 20( 10): 1626– 1633
CrossRef Google scholar
[85]
BlancoE, BeyE A, KhemtongC, YangS G, Setti-GuthiJ, ChenH, KessingerC W, CarnevaleK A, BornmannW G, BoothmanD A, GaoJ. β-Lapachone micellar nanotherapeutics for non-small cell lung cancer therapy. Cancer Research, 2010, 70( 10): 3896– 3904
CrossRef Google scholar
[86]
ZhangD, YangJ, GuanJ, YangB, ZhangS, SunM, YangR, ZhangT, ZhangR, KanQ, ZhangH, HeZ, ShangL, SunJ. In vivo tailor-made protein corona of a prodrug-based nanoassembly fabricated by redox dual-sensitive paclitaxel prodrug for the superselective treatment of breast cancer. Biomaterials Science, 2018, 6( 9): 2360– 2374
CrossRef Google scholar
[87]
LiM, ZhaoL, ZhangT, ShuY, HeZ, MaY, LiuD, WangY. Redox-sensitive prodrug nanoassemblies based on linoleic acid-modified docetaxel to resist breast cancers. Acta Pharmaceutica Sinica. B, 2019, 9( 2): 421– 432
CrossRef Google scholar
[88]
WangK, YangB, YeH, ZhangX, SongH, WangX, LiN, WeiL, WangY, ZhangH, KanQ, HeZ, WangD, SunJ. Self-strengthened oxidation-responsive bioactivating prodrug nanosystem with sequential and synergistically facilitated drug release for treatment of breast cancer. ACS Applied Materials & Interfaces, 2019, 11( 21): 18914– 18922
CrossRef Google scholar
[89]
GanesanM, KanimozhiG, PradhapsinghB, KhanH A, AlhomidaA S, EkhzaimyA, BrindhaG R, PrasadN R. Phytochemicals reverse P-glycoprotein mediated multidrug resistance via signal transduction pathways. Biomedicine and Pharmacotherapy, 2021, 139 : 111632
CrossRef Google scholar
[90]
YanY, OchsC J, SuchG K, HeathJ K, NiceE C, CarusoF. Bypassing multidrug resistance in cancer cells with biodegradable polymer capsules. Advanced Materials, 2010, 22( 47): 5398– 5403
CrossRef Google scholar
[91]
CheL, LiuZ, WangD, XuC, ZhangC, MengJ, ZhengJ, YuanH, ZhaoG, ZhouX. Computer-assisted engineering of programmed drug releasing multilayer nanomedicine via indomethacin-mediated ternary complex for therapy against a multidrug resistant tumor. Acta Biomaterialia, 2019, 97 : 461– 473
CrossRef Google scholar
[92]
ChangN, ZhaoY, GeN, QianL. A pH/ROS cascade-responsive and self-accelerating drug release nanosystem for the targeted treatment of multi-drug-resistant colon cancer. Drug Delivery, 2020, 27( 1): 1073– 1086
CrossRef Google scholar
[93]
LiQ, HouW, LiM, YeH, LiH, WangZ. Ultrasound combined with core cross-linked nanosystem for enhancing penetration of doxorubicin prodrug/beta-lapachone into tumors. International Journal of Nanomedicine, 2020, 15 : 4825– 4845
CrossRef Google scholar
[94]
YeM, HanY, TangJ, PiaoY, LiuX, ZhouZ, GaoJ, RaoJ, ShenY. A tumor-specific cascade amplification drug release nanoparticle for overcoming multidrug resistance in cancers. Advanced Materials, 2017, 29( 38): 1702342
CrossRef Google scholar
[95]
TangZ, ZhangH, LiuY, NiD, ZhangH, ZhangJ, YaoZ, HeM, ShiJ, BuW. Antiferromagnetic pyrite as the tumor microenvironment-mediated nanoplatform for self-enhanced tumor imaging and therapy. Advanced Materials, 2017, 29( 47): 1701683
CrossRef Google scholar
[96]
DaiY, YangZ, ChengS, WangZ, ZhangR, ZhuG, WangZ, YungB C, TianR, JacobsonO, XuC, NiQ, SongJ, SunX, NiuG, ChenX. Toxic reactive oxygen species enhanced synergistic combination therapy by self-assembled metal-phenolic network nanoparticles. Advanced Materials, 2018, 30( 8): 1704877
CrossRef Google scholar
[97]
HuoM, WangL, ChenY, ShiJ. Tumor-selective catalytic nanomedicine by nanocatalyst delivery. Nature Communications, 2017, 8( 1): 357
CrossRef Google scholar
[98]
LiuM, XuY, ZhaoY, WangZ, ShiD. Hydroxyl radical-involved cancer therapy via fenton reactions. Frontiers of Chemical Science and Engineering, 2022, 16( 3): 345– 363
CrossRef Google scholar
[99]
ZhangM, QinX, ZhaoZ, DuQ, LiQ, JiangY, LuanY. A self-amplifying nanodrug to manipulate the janus-faced nature of ferroptosis for tumor therapy. Nanoscale Horizons, 2022, 7( 2): 198– 210
CrossRef Google scholar
[100]
ChenZ, YinJ J, ZhouY T, ZhangY, SongL, SongM, HuS, GuN. Dual enzyme-like activities of iron oxide nanoparticles and their implication for diminishing cytotoxicity. ACS Nano, 2012, 6( 5): 4001– 4012
CrossRef Google scholar
[101]
GaoL, ZhuangJ, NieL, ZhangJ, ZhangY, GuN, WangT, FengJ, YangD, PerrettS, YanX. Intrinsic peroxidase-like activity of ferromagnetic nanoparticles. Nature Nanotechnology, 2007, 2( 9): 577– 583
CrossRef Google scholar
[102]
ChenQ, ZhouJ, ChenZ, LuoQ, XuJ, SongG. Tumor-specific expansion of oxidative stress by glutathione depletion and use of a fenton nanoagent for enhanced chemodynamic therapy. ACS Applied Materials & Interfaces, 2019, 11( 34): 30551– 30565
CrossRef Google scholar
[103]
TianH, ZhangM, JinG, JiangY, LuanY. Cu-MOF chemodynamic nanoplatform via modulating glutathione and H2O2 in tumor microenvironment for amplified cancer therapy. Journal of Colloid and Interface Science, 2021, 587 : 358– 366
CrossRef Google scholar
[104]
PeerD, KarpJ M, HongS, FarokhzadO C, MargalitR, LangerR. Nanocarriers as an emerging platform for cancer therapy. Nature Nanotechnology, 2007, 2( 12): 751– 760
CrossRef Google scholar
[105]
ConnorE E, MwamukaJ, GoleA, MurphyC J, WyattM D. Gold nanoparticles are taken up by human cells but do not cause acute cytotoxicity. Small, 2005, 1( 3): 325– 327
CrossRef Google scholar
[106]
HanG, GhoshP, RotelloV M. Functionalized gold nanoparticles for drug delivery. Nanomedicine, 2007, 2( 1): 113– 123
CrossRef Google scholar
[107]
JeongS Y, ParkS J, YoonS M, JungJ, WooH N, YiS L, SongS Y, ParkH J, KimC, LeeJ S, LeeJ S, ChoiE K. Systemic delivery and preclinical evaluation of Au nanoparticle containing beta-lapachone for radiosensitization. Journal of Controlled Release, 2009, 139( 3): 239– 245
CrossRef Google scholar
[108]
BeyE A, BentleM S, ReinickeK E, DongY, YangC R, GirardL, MinnaJ D, BornmannW G, GaoJ, BoothmanD A. An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by β-lapachone. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104( 28): 11832– 11837
CrossRef Google scholar
[109]
HuangX, MoteaE A, MooreZ R, YaoJ, DongY, ChakrabartiG, KilgoreJ A, SilversM A, PatidarP L, CholkaA, FattahF, ChaY, AndersonG G, KuskoR, PeytonM, YanJ, XieX J, SarodeV, WilliamsN S, MinnaJ D, BegM, GerberD E, BeyE A, BoothmanD A. Leveraging an NQO1 bioactivatable drug for tumor-selective use of poly(ADP-ribose) polymerase inhibitors. Cancer Cell, 2016, 30( 6): 940– 952
CrossRef Google scholar
[110]
ZhouL, ChenJ, SunY, ChaiK, ZhuZ, WangC, ChenM, HanW, HuX, LiR, YaoT, LiH, DongC, ShiS. A self-amplified nanocatalytic system for achieving “1 + 1 + 1 > 3” chemodynamic therapy on triple negative breast cancer. Journal of Nanobiotechnology, 2021, 19( 1): 261
CrossRef Google scholar
[111]
ZhangL, ChenZ, YangK, LiuC, GaoJ, QianF. β-Lapachone and paclitaxel combination micelles with improved drug encapsulation and therapeutic synergy as novel nanotherapeutics for NQO1-targeted cancer therapy. Molecular Pharmaceutics, 2015, 12( 11): 3999– 4010
CrossRef Google scholar
[112]
LiX, JiaX, NiuH. Nanostructured lipid carriers co-delivering lapachone and doxorubicin for overcoming multidrug resistance in breast cancer therapy. International Journal of Nanomedicine, 2018, 13 : 4107– 4119
CrossRef Google scholar
[113]
DongX, LiuH J, FengH Y, YangS C, LiuX L, LaiX, LuQ, LovellJ F, ChenH Z, FangC. Enhanced drug delivery by nanoscale integration of a nitric oxide donor to induce tumor collagen depletion. Nano Letters, 2019, 19( 2): 997– 1008
CrossRef Google scholar
[114]
ChuC, LyuX, WangZ, JinH, LuS, XingD, HuX. Cocktail polyprodrug nanoparticles concurrently release cisplatin and peroxynitrite-generating nitric oxide in cisplatin-resistant cancers. Chemical Engineering Journal, 2020, 402 : 126125
CrossRef Google scholar
[115]
ZhangK, XuH, JiaX, ChenY, MaM, SunL, ChenH. Ultrasound-triggered nitric oxide release platform based on energy transformation for targeted inhibition of pancreatic tumor. ACS Nano, 2016, 10( 12): 10816– 10828
CrossRef Google scholar
[116]
WanM, ChenH, WangQ, NiuQ, XuP, YuY, ZhuT, MaoC, ShenJ. Bio-inspired nitric-oxide-driven nanomotor. Nature Communications, 2019, 10( 1): 966
CrossRef Google scholar
[117]
QinL, GaoH. The application of nitric oxide delivery in nanoparticle-based tumor targeting drug delivery and treatment. Asian Journal of Pharmaceutical Sciences, 2019, 14( 4): 380– 390
CrossRef Google scholar
[118]
VongL B, NagasakiY. Nitric oxide nano-delivery systems for cancer therapeutics: advances and challenges. Antioxidants, 2020, 9( 9): 791
CrossRef Google scholar
[119]
AnJ, HuY G, LiC, HouX L, ChengK, ZhangB, ZhangR Y, LiD Y, LiuS J, LiuB, ZhuD, ZhaoY D. A pH/ultrasound dual-response biomimetic nanoplatform for nitric oxide gas-sonodynamic combined therapy and repeated ultrasound for relieving hypoxia. Biomaterials, 2020, 230 : 119636
CrossRef Google scholar
[120]
YuanZ, LinC, HeY, TaoB, ChenM, ZhangJ, LiuP, CaiK. Near-infrared light-triggered nitric-oxide-enhanced photodynamic therapy and low-temperature photothermal therapy for biofilm elimination. ACS Nano, 2020, 14( 3): 3546– 3562
CrossRef Google scholar
[121]
ShiM, ZhangJ, WangY, PengC, HuH, QiaoM, ZhaoX, ChenD. Tumor-specific nitric oxide generator to amplify peroxynitrite based on highly penetrable nanoparticles for metastasis inhibition and enhanced cancer therapy. Biomaterials, 2022, 283 : 121448
CrossRef Google scholar
[122]
LeeJ, OhE T, YoonH, KimC W, HanY, SongJ, JangH, ParkH J, KimC. Mesoporous nanocarriers with a stimulus-responsive cyclodextrin gatekeeper for targeting tumor hypoxia. Nanoscale, 2017, 9( 20): 6901– 6909
CrossRef Google scholar
[123]
GayamS R, VenkatesanP, SungY M, SungS Y, HuS H, HsuH Y, WuS P. An NAD(P)H:quinone oxidoreductase 1 (NQO1) enzyme responsive nanocarrier based on mesoporous silica nanoparticles for tumor targeted drug delivery in vitro and in vivo. Nanoscale, 2016, 8( 24): 12307– 12317
CrossRef Google scholar

Acknowledgments

The authors acknowledge the financial support from the Tianjin Science and Technology Committee (Grant No. 19JCYBJC28400), the Basic Research General Program of Shenzhen Science and Technology Innovation Commission in 2020 (Grant No. JCYJ20190806162412752).

RIGHTS & PERMISSIONS

2022 Higher Education Press
AI Summary AI Mindmap
PDF(8156 KB)

Accesses

Citations

Detail

Sections
Recommended

/